Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with <i>BRAF</i>^V600 mutation–positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study.

Brigitte Dréno, James Larkin, Mario Mandalà et al.|Journal of Clinical Oncology|2018

Cited by 27